2005
DOI: 10.1002/14651858.cd004139.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukaemia

Abstract: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections. However, there was no evidence for a shortened duration of neutropenia nor fewer treatment delays, and no useful information about survival. The role of CSF regarding febrile neutropenia episodes is still uncertain. Although current data shows statistical benefit for CSF use, substantial heterogeneity between included trials does not allow this conclusion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
21
0

Year Published

2008
2008
2015
2015

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(21 citation statements)
references
References 68 publications
0
21
0
Order By: Relevance
“…Filgrastin, a colony-stimulating factor, was used in this case as means to decrease the duration of clozapineinduced neutropenia. Its presumed efficacy is based on case reports [19][20] and studies in cancer patients under cytotoxic chemotherapy [21]. Given that protective mechanical ventilation and appropriate restoration of tissue through fluid challenge and vasopressor are two measures associated with better outcomes in critically ill patients, they likely played important roles in the positive outcome reported here [18].…”
Section: Discussionmentioning
confidence: 98%
“…Filgrastin, a colony-stimulating factor, was used in this case as means to decrease the duration of clozapineinduced neutropenia. Its presumed efficacy is based on case reports [19][20] and studies in cancer patients under cytotoxic chemotherapy [21]. Given that protective mechanical ventilation and appropriate restoration of tissue through fluid challenge and vasopressor are two measures associated with better outcomes in critically ill patients, they likely played important roles in the positive outcome reported here [18].…”
Section: Discussionmentioning
confidence: 98%
“…G-CSF has been also given to AML patients to shorten febrile neutropenia period after induction therapy [7,20]. In childhood ALL the use of G-CSF has become widespread to shorten febrile neutropenic period, since under physiological circumstances G-CSF does not have any influence on the proliferation/differentiation pathways in lymphoid lineage, therefore it is thought that G-CSF has no effect on ALL blasts [4].…”
Section: Discussionmentioning
confidence: 99%
“…At the same time stimulatory effects of G-CSF on leukaemic lymphoblasts are unexpected, since according to our current knowledge it does not have any influence on pathways of proliferation and differentiation in the lymphoid lineage [21]. Although, the effects of these GFs at a cellular level are not well understood, the clinical use of G-CSF to minimize chemotherapy-induced myelosuppression in childhood ALL has become more widespread [4,22].…”
Section: Introductionmentioning
confidence: 94%
See 1 more Smart Citation
“…Thus, a systematic review on the use of colony-stimulating factors in patients with hematologic malignancies will be a far greater undertaking than a systematic review of colony-stimulating factors in preventing chemotherapy-induced febrile neutropenia in children with acute lymphoblastic leukemia. 10 When reading a systematic review one must always ascertain that the investigators are answering the question originally posed. A major cause of bias in a systematic review is answering a different question to that originally asked.…”
Section: The Clinical Questionmentioning
confidence: 99%